Chimerix Back On Track, Focusing On Phase III Program For CMV Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
Brincidofovir could be the first drug approved to suppress cytomegalovirus infections in bone marrow transplant patients. A 450-patient Phase III trial is enrolling patients now with data expected around mid-2015.